Anifrolumab
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
Pressure score
52
Momentum score
5
Why This Matters
Bristol Myers Squibb is a direct competitive threat because it has a development-stage program in Immunology · Systemic Lupus Erythematosus (Anifrolumab) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
Bristol Myers Squibb document relevant to the signal.
Source: Bristol Myers Squibb
View source documentRelated Signal
AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Roche
4 competitive findings
Top program: Anifrolumab
- Pressure
- 65
- Momentum
- 5
- Threat
- regulatory competitor
- Stage
- Stage unknown
65RocheMediumAnifrolumab·Stage unknown
Bristol Myers Squibb
1 competitive finding
Top program: Anifrolumab
- Pressure
- 52
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
52Bristol Myers SquibbMediumAnifrolumab·Stage unknown